Drug information for FLUPHENAZINE DECANOATE

Form Dosage Status Therapeutic Equivalence Active Ingred Ref. Sponsor Document
INJECTABLE; INJECTION 25MG/ML Prescription AO (Reference Drug) FLUPHENAZINE DECANOATE fluphenazine depot APP PHARMS 71413
2011-10-07 Letter
2011-10-06 Label
INJECTABLE; INJECTION 25MG/ML Prescription AO  FLUPHENAZINE DECANOATE fluphenazine depot BEDFORD 74531
INJECTABLE; INJECTION 25MG/ML Discontinued   FLUPHENAZINE DECANOATE fluphenazine depot TEVA PARENTERAL 74795
2011-05-06 Review
INJECTABLE; INJECTION 25MG/ML Discontinued   FLUPHENAZINE DECANOATE fluphenazine depot HOSPIRA 74966
1998-04-16 Letter
INJECTABLE; INJECTION 25MG/ML Prescription AO  FLUPHENAZINE DECANOATE fluphenazine depot CLARIS LIFESCIENCES 75918
2007-07-06 Review

Drug Adverse Effects information for FLUPHENAZINE DECANOATE

Role code Indications Reaction # Reports
PS SCHIZOPHRENIA TARDIVE DYSKINESIA 1
SS PARKINSONISM ANAEMIA 4
SS PARKINSONISM DEHYDRATION 4
SS PARKINSONISM ILEUS 4
SS PARKINSONISM INFECTION 4
SS PARKINSONISM INFLAMMATION 4
SS PARKINSONISM MALABSORPTION 4
SS PARKINSONISM NEUROLEPTIC MALIGNANT SYNDROME 4
SS PARKINSONISM PERSECUTORY DELUSION 4
SS PARKINSONISM PNEUMONIA 4
SS PARKINSONISM RENAL IMPAIRMENT 4
SS PARKINSONISM RESPIRATORY FAILURE 4
SS PARKINSONISM WHITE BLOOD CELL COUNT INCREASED 4
SS SCHIZOPHRENIA ANAEMIA 3
SS SCHIZOPHRENIA DEHYDRATION 3
SS SCHIZOPHRENIA ILEUS 3
SS SCHIZOPHRENIA INFECTION 3
SS SCHIZOPHRENIA INFLAMMATION 3
SS SCHIZOPHRENIA MALABSORPTION 3
SS SCHIZOPHRENIA NEUROLEPTIC MALIGNANT SYNDROME 3
SS SCHIZOPHRENIA PERSECUTORY DELUSION 3
SS SCHIZOPHRENIA PNEUMONIA 3
SS SCHIZOPHRENIA RENAL IMPAIRMENT 3
SS SCHIZOPHRENIA RESPIRATORY FAILURE 3
SS SCHIZOPHRENIA WHITE BLOOD CELL COUNT INCREASED 3
C ABNORMAL BEHAVIOUR AFFECTIVE DISORDER 1
C ABNORMAL BEHAVIOUR ANTICONVULSANT DRUG LEVEL INCREASED 1
C ABNORMAL BEHAVIOUR COAGULATION FACTOR DECREASED 1
C ABNORMAL BEHAVIOUR CONVULSION 1
C ABNORMAL BEHAVIOUR DRUG EFFECT DECREASED 1
C ABNORMAL BEHAVIOUR FALL 1
C ABNORMAL BEHAVIOUR LACERATION 1
C ABNORMAL BEHAVIOUR PLATELET AGGREGATION DECREASED 1
C ABNORMAL BEHAVIOUR RENAL DISORDER 1
C ABNORMAL BEHAVIOUR SUICIDAL BEHAVIOUR 1
C ABNORMAL BEHAVIOUR VON WILLEBRAND'S DISEASE 1
C ABNORMAL BEHAVIOUR WOUND HAEMORRHAGE 1
C EPILEPSY AFFECTIVE DISORDER 4
C EPILEPSY ANTICONVULSANT DRUG LEVEL INCREASED 4
C EPILEPSY COAGULATION FACTOR DECREASED 4
C EPILEPSY CONVULSION 4
C EPILEPSY DRUG EFFECT DECREASED 4
C EPILEPSY FALL 4
C EPILEPSY LACERATION 4
C EPILEPSY PLATELET AGGREGATION DECREASED 4
C EPILEPSY RENAL DISORDER 4
C EPILEPSY SUICIDAL BEHAVIOUR 4
C EPILEPSY VON WILLEBRAND'S DISEASE 4
C EPILEPSY WOUND HAEMORRHAGE 4
C PARKINSON'S DISEASE AFFECTIVE DISORDER 1
C PARKINSON'S DISEASE ANTICONVULSANT DRUG LEVEL INCREASED 1
C PARKINSON'S DISEASE COAGULATION FACTOR DECREASED 1
C PARKINSON'S DISEASE CONVULSION 1
C PARKINSON'S DISEASE DRUG EFFECT DECREASED 1
C PARKINSON'S DISEASE FALL 1
C PARKINSON'S DISEASE LACERATION 1
C PARKINSON'S DISEASE PLATELET AGGREGATION DECREASED 1
C PARKINSON'S DISEASE RENAL DISORDER 1
C PARKINSON'S DISEASE SUICIDAL BEHAVIOUR 1
C PARKINSON'S DISEASE VON WILLEBRAND'S DISEASE 1
C PARKINSON'S DISEASE WOUND HAEMORRHAGE 1
C PRODUCT USED FOR UNKNOWN INDICATION AFFECTIVE DISORDER 4
C PRODUCT USED FOR UNKNOWN INDICATION ANTICONVULSANT DRUG LEVEL INCREASED 4
C PRODUCT USED FOR UNKNOWN INDICATION COAGULATION FACTOR DECREASED 4
C PRODUCT USED FOR UNKNOWN INDICATION CONVULSION 4
C PRODUCT USED FOR UNKNOWN INDICATION DRUG EFFECT DECREASED 4
C PRODUCT USED FOR UNKNOWN INDICATION FALL 4
C PRODUCT USED FOR UNKNOWN INDICATION LACERATION 4
C PRODUCT USED FOR UNKNOWN INDICATION PLATELET AGGREGATION DECREASED 4
C PRODUCT USED FOR UNKNOWN INDICATION RENAL DISORDER 4
C PRODUCT USED FOR UNKNOWN INDICATION SUICIDAL BEHAVIOUR 4
C PRODUCT USED FOR UNKNOWN INDICATION VON WILLEBRAND'S DISEASE 4
C PRODUCT USED FOR UNKNOWN INDICATION WOUND HAEMORRHAGE 4
Ads by Google